• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FLUOROURACIL Drug Record

  • Summary
  • Interactions
  • Claims
  • FLUOROURACIL chembl:CHEMBL185 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    FLURACIL
    ACTIKERALL
    CARAC
    EFUDEX
    FLUOROPLEX
    ACCUSITE
    RO-29757
    5.F.U.
    FLUORO-URACIL ROCHE
    NSC-19893
    5 FU
    ADRUCIL
    EFUDIX
    TOLAK
    5-FU
    5-FLUOROURACIL
    RO-2-9757
    FLUOROURACIL
    FLUOROURACILO
    FLUORURACIL
    CARAC®
    FLUOURACIL
    FU
    FLUOROURACILUM
    FLUORO URACIL
    5-FLUORACIL
    5-FLUOROPYRIMIDINE-2,4-DIONE
    5-FLURACIL
    ADRUCIL®
    rxcui:4492
    pubchem.compound:3385
    drugbank:00544
    chemidplus:51-21-8
    chembl:CHEMBL185

    Drug Info:

    (10 More Sources)

    Publications:

    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Nikas et al., 2015, A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer., Am J Cancer Res
    Huang et al., 2009, The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Cancer Chemother. Pharmacol.
    Yousef AM et al., 2018, The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer., Cancer Chemother Pharmacol
    Nahid NA et al., 2018, DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer., Cancer Chemother Pharmacol
    Meulendijks D et al., 2017, Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies., Pharmacogenomics J
    Roberto M et al., 2017, Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine., Eur J Clin Pharmacol
    Borro M et al., 2017, Pre-treatment assay of 5-fluorouracil degradation rate (5-FUDR) to improve prediction of 5-fluorouracil toxicity in gastro-esophageal cancer., Oncotarget
    Romiti A et al., 2016, The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer., Anticancer Drugs
    Mazzuca F et al., 2016, Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort., Oncotarget
    Chaturvedi P et al., 2015, Relationship of MTHFR and NQO1 Pharmacogenetics and Chemotherapy Clinical Outcomes in Breast Cancer Patients., Biochem Genet
    Cecchin E et al., 2015, MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin., Pharmacogenomics J
    Custodio A et al., 2014, Pharmacogenetic predictors of outcome in patients with stage II and III colon cancer treated with oxaliplatin and fluoropyrimidine-based adjuvant chemotherapy., Mol Cancer Ther
    Jennings BA et al., 2013, Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines., PLoS One
    Loganayagam A et al., 2013, Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity., Br J Cancer
    van Huis-Tanja LH et al., 2013, MTHFR polymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer., Pharmacogenet Genomics
    Lee KH et al., 2013, Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer., Cancer Chemother Pharmacol
    Kristensen MH et al., 2010, Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients., J Int Med Res
    Henríquez-Hernández LA et al., 2010, Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy., Cancer Epidemiol
    Boige V et al., 2010, Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05., J Clin Oncol
    Gusella M et al., 2009, Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer., Br J Cancer
    Schwab M et al., 2008, Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group., J Clin Oncol
    Sharma R et al., 2008, Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients., Clin Cancer Res
    Capitain O et al., 2008, The influence of fluorouracil outcome parameters on tolerance and efficacy in patients with advanced colorectal cancer., Pharmacogenomics J
    Schwahn B et al., 2001, Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences., Am J Pharmacogenomics
    Ruzzo A et al., 2008, Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy., Pharmacogenomics J
    Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem
    Huang et al., 2006, Tailor-made chemotherapy for non-small cell lung cancer patients., Future Oncol
    Garcia et al., 2006, Thymidylate synthase messenger RNA expression in plasma from patients with colon cancer: prognostic potential., Clin. Cancer Res.
    Fernández-Contreras et al., 2006, Thymidylate synthase expression pattern, expression level and single nucleotide polymorphism are predictors for disease-free survival in patients of colorectal cancer treated with 5-fluorouracil., Int. J. Oncol.
    Formentini et al., 2007, Thymidylate synthase expression in resectable and unresectable pancreatic cancer: role as predictive or prognostic marker?, Int J Colorectal Dis
    Ploylearmsaeng et al., 2006, How may anticancer chemotherapy with fluorouracil be individualised?, Clin Pharmacokinet
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Rustum, 2004, Thymidylate synthase: a critical target in cancer therapy?, Front. Biosci.
    Martinez-Balibrea et al., 2010, UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy., Br. J. Cancer
    Singh V et al., 2015, The complex mechanism of antimycobacterial action of 5-fluorouracil., Chem Biol
    Absenger G et al., 2014, The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy., Pharmacogenomics J
    Lamas MJ et al., 2011, Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer., Pharmacogenomics
    Agostini M et al., 2008, Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy., Drugs Aging
    Budai B et al., 2012, Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab., Pharmacogenet Genomics
    Saliba J et al., 2016, Pharmacogenetic characterization of naturally occurring germline NT5C1A variants to chemotherapeutic nucleoside analogs., Pharmacogenet Genomics
    Cheng L et al., 2017, Functional genetic variants of XRCC4 and ERCC1 predict survival of gastric cancer patients treated with chemotherapy by regulating the gene expression., Mol Carcinog
    Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J
    Nishio et al., 1996, Changes in markers, receptors and adhesion molecules expressed on murine hemopoietic stem cells after a single injection of 5-fluorouracil., Stem Cells
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
    Hirano et al., Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs., Anticancer Res.
    Yang YC et al., 2017, Association of thymidylate synthase polymorphisms with the tumor response to preoperative chemoradiotherapy in rectal cancer: a systematic review and meta-analysis., Pharmacogenomics J
    Gao J et al., 2013, Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel., Clin Transl Oncol
    Kim SR et al., 2010, Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity., Chemotherapy
    Boulay et al., 2002, SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer., Br. J. Cancer
    Musashi et al., 1991, Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice., Blood
    Katayama et al., 1993, Stage-specific expression of c-kit protein by murine hematopoietic progenitors., Blood
    Park et al., 2003, Inhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomes., Eur. J. Clin. Pharmacol.
    Sim et al., 2014, P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer., BMC Cancer
    Saif et al., 2006, Dihydropyrimidine dehydrogenase deficiency in an Indian population., Cancer Chemother. Pharmacol.
    Jakob et al., 2004, Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer., J. Pathol.
    Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J
    Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.
    Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
    Majounie E et al., 2020, Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic <i>DPYD</i> structural variant., Cold Spring Harb Mol Case Stud
    Caudle et al., 2013, Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing., Clin. Pharmacol. Ther.
    Herath et al., 2016, The DNA Repair Inhibitor DT01 as a Novel Therapeutic Strategy for Chemosensitization of Colorectal Liver Metastasis., Mol. Cancer Ther.
    Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud
    Chung et al., 2006, XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer., Gynecol. Oncol.
    Aguilera et al., 2015, Nuclear DICKKOPF-1 as a biomarker of chemoresistance and poor clinical outcome in colorectal cancer., Oncotarget
    Langer et al., 2004, [Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis]., Verh Dtsch Ges Pathol
    Tajima et al., 2003, Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil., J. Cancer Res. Clin. Oncol.
    de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.
    Tsunoda A et al., 2011, Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study., Ann Oncol
    Ichikawa W et al., 2006, Orotate phosphoribosyltransferase gene polymorphism predicts toxicity in patients treated with bolus 5-fluorouracil regimen., Clin Cancer Res
    Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
    Xu et al., 2017, PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer., Clin. Cancer Res.
    Bhattacharya et al., 2012, Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells., Cancer Biol. Ther.
    Lin CC et al., 2020, A GALNT14 rs9679162 genotype-guided therapeutic strategy for advanced hepatocellular carcinoma: systemic or hepatic arterial infusion chemotherapy., Pharmacogenomics J
    Liang KH et al., 2011, GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC., Pharmacogenomics
    Graidist et al., 2004, Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity., J. Biol. Chem.
    Takemura et al., 2005, Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy., J. Oral Pathol. Med.
    Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
    Takahashi H et al., 2013, Identification of a candidate single-nucleotide polymorphism related to chemotherapeutic response through a combination of knowledge-based algorithm and hypothesis-free genomic data., J Biosci Bioeng
    Alakus et al., 2009, GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer., Pharmacogenomics J.
    Chéradame et al., 1997, Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data., Eur. J. Cancer
    Low SK et al., 2009, Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients., J Hum Genet
    Kummer D et al., 2015, Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity., Pharmacogenomics
    Nylén et al., 1998, Cisplatin-induced inhibition of p34cdc2 is abolished by 5-fluorouracil., Acta Oncol
    Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
    Iwahashi K et al., 2004, Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior., Neuropsychobiology
    Wang H et al., 2011, Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes., Pharmacogenomics
    Tanii H et al., 2011, Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women., Eur J Clin Pharmacol
    Djordjevic N et al., 2010, In vivo evaluation of CYP2A6 and xanthine oxidase enzyme activities in the Serbian population., Eur J Clin Pharmacol
    Ishii Y et al., 2010, Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?, Cancer Chemother Pharmacol
    Kong SY et al., 2009, Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer., Pharmacogenomics
    di Iulio J et al., 2009, In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function., Pharmacogenet Genomics
    Endo T et al., 2008, Genetic polymorphisms of CYP2A6 affect the in-vivo pharmacokinetics of pilocarpine., Pharmacogenet Genomics
    Wang J et al., 2006, 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression., Biochem Biophys Res Commun
    Gambier N et al., 2005, Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort., Pharmacogenomics J
    Páez D et al., 2014, Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence., Pharmacogenomics J
    Graziano F et al., 2010, Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy., Pharmacogenomics
    Balaji et al., 1997, Effect of 5-fluorouracil on interleukin-1 and interleukin-2 receptor expression., Biochem. Mol. Biol. Int.
    Huang MY et al., 2011, Multiple genetic polymorphisms in the prediction of clinical outcome of metastatic colorectal cancer patients treated with first-line FOLFOX-4 chemotherapy., Pharmacogenet Genomics
    Fujishima et al., 1997, Inhibition by 5-fluorouracil of ERCC1 and gamma-glutamylcysteine synthetase messenger RNA expression in a cisplatin-resistant HST-1 human squamous carcinoma cell line., Oncol. Res.
    Iwase et al., 2003, Enhanced susceptibility of oral squamous cell carcinoma cell lines to FAS-mediated apoptosis by cisplatin and 5-fluorouracil., Int. J. Cancer
    Magdy T et al., 2013, ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression., Pharmacogenomics
    Szkandera J et al., 2015, LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy., Pharmacogenomics J
    Chen S et al., 2015, ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients., Pharmacogenet Genomics
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Banerjee et al., 1998, Role of E2F-1 in chemosensitivity., Cancer Res.
    Wang L et al., 2015, Association between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-Analysis., PLoS One
    Scartozzi M et al., 2013, Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients., Pharmacogenomics
    Hansen TF et al., 2011, The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer., Pharmacogenomics J
    Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
    Douillard et al., 2010, Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study., J. Clin. Oncol.
    Kakiuchi et al., 2004, Flow cytometric analyses on lineage-specific cell surface antigens of rat bone marrow to seek potential myelotoxic biomarkers: status after repeated dose of 5-fluorouracil., J Toxicol Sci
    Zhao J et al., 2014, Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer., Med Oncol
    De Mattia E et al., 2013, Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment., Pharmacogenet Genomics
    McLeod HL et al., 2010, Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741., J Clin Oncol
    Meulendijks D et al., 2016, Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity., Int J Cancer
    Falvella FS et al., 2015, DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan., Br J Clin Pharmacol
    Amstutz U et al., 2015, Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy., Clin Cancer Res
    Offer SM et al., 2014, microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites., Mol Cancer Ther
    Thussbas C et al., 2006, FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer., J Clin Oncol
    Fernandez-Rozadilla C et al., 2013, Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration., Pharmacogenomics J
    Feng et al., 2013, Cbl-b enhances sensitivity to 5-fluorouracil via EGFR- and mitochondria-mediated pathways in gastric cancer cells., Int J Mol Sci
    Khrunin AV et al., 2014, Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer., Pharmacogenomics
    Jamieson D et al., 2011, Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy., Pharmacogenet Genomics
    Kolesar JM et al., 2011, The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer., Oncol Rep
    Fagerholm R et al., 2008, NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer., Nat Genet
    Siegel D et al., 2001, Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1., Mol Pharmacol
    Siegel D et al., 1999, Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1., Pharmacogenetics
    Volz NB et al., 2015, Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer., Pharmacogenomics J
    Di Renzo et al., 1977, Effects of some antineoplastic agents on plasma levels of corticosterone, prolactin and thyroid stimulating hormone., Arch Int Pharmacodyn Ther
    Thornton et al., 2013, The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer., Int. J. Cancer
    Hamad et al., 2017, Neoadjuvant Treatment With Trastuzumab and FOLFOX Induces a Complete Pathologic Response in a Metastatic ERBB2 (HER2)-Amplified Duodenal Cancer., J Natl Compr Canc Netw
    Mustafa et al., 2008, 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus., Eur. J. Neurosci.
  • FLUOROURACIL   MIR27A

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26804235 25782327 25655103 24401318


    Sources:
    PharmGKB

  • FLUOROURACIL   LGR5

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25665511


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCC11

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24024896


    Sources:
    PharmGKB

  • FLUOROURACIL   WNT5B

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23817222


    Sources:
    PharmGKB

  • FLUOROURACIL   TPT1

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15262975


    Sources:
    NCI

  • FLUOROURACIL   ALCAM

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24708484


    Sources:
    CIViC

  • FLUOROURACIL   MEGF11

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • FLUOROURACIL   CHN2

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • FLUOROURACIL   TMEM167A

    Interaction Score: 1.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28796378


    Sources:
    PharmGKB

  • FLUOROURACIL   DPYD

    Interaction Score: 0.72

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16421754 15538739 11501504 15330204 17179731 31871216 23988873


    Sources:
    NCI CIViC TTD FDA

  • FLUOROURACIL   ENOSF1

    Interaction Score: 0.71

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27995989 27001118 23263912 20714149 17549067


    Sources:
    PharmGKB

  • FLUOROURACIL   MTHFR

    Interaction Score: 0.61

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26693073 18704422 29845393 29134491 27995989 27864592 27738344 27557140 26967565 26014925 25331073 24980946 24167597 23736036 23407049 23314736 20819423 20638924 20385995 19384296 18299612 18245544 17700593 12083967


    Sources:
    CIViC PharmGKB

  • FLUOROURACIL   CBLB

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Indication/Tumor Type stomach cancer
    Response Type decreased response

    PMIDs:
    24351824


    Sources:
    JAX-CKB

  • FLUOROURACIL   PARD3B

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22310351


    Sources:
    PharmGKB

  • FLUOROURACIL   XRCC4

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28796378


    Sources:
    PharmGKB

  • FLUOROURACIL   IGFBP3

    Interaction Score: 0.59

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20860465


    Sources:
    PharmGKB

  • FLUOROURACIL   GALNT14

    Interaction Score: 0.44

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    31611591 21635146


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCG1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • FLUOROURACIL   XRCC3

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • FLUOROURACIL   DPYS

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26244261


    Sources:
    PharmGKB

  • FLUOROURACIL   FPGS

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9291820


    Sources:
    NCI

  • FLUOROURACIL   MYB

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15001837


    Sources:
    NCI

  • FLUOROURACIL   MUC2

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14576935


    Sources:
    NCI

  • FLUOROURACIL   TYMP

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11205264 24167597


    Sources:
    NCI PharmGKB

  • FLUOROURACIL   NT5C1A

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26906009


    Sources:
    PharmGKB

  • FLUOROURACIL   KLC1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17549067


    Sources:
    PharmGKB

  • FLUOROURACIL   UMPS

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20647221 16818689


    Sources:
    PharmGKB

  • FLUOROURACIL   EXO1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   RGS5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25069475


    Sources:
    PharmGKB

  • FLUOROURACIL   DLG5

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   CDC25C

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9743457


    Sources:
    NCI

  • FLUOROURACIL   DTYMK

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15067352


    Sources:
    NCI

  • FLUOROURACIL   CYP2A6

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14981342 21521021 21494765 20155256 19921195 19604090 19238117 18698229 16378601 15940289


    Sources:
    PharmGKB

  • FLUOROURACIL   IL11

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    1832057 7691257


    Sources:
    NCI

  • FLUOROURACIL   SHMT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22044939


    Sources:
    PharmGKB

  • FLUOROURACIL   NQO1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25545243 24533712 21946896 21479364 18511948 11160862 10208650


    Sources:
    PharmGKB

  • FLUOROURACIL   TYMS

    Interaction Score: 0.22

    Interaction Types & Directionality:
    other/unknown
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Thymidylate synthase inhibitor
    Direct Interaction yes

    PMIDs:
    24450514 16563096 16609021 16596248 16538493 16719540 11752352 15353299 20628391 25544046


    Sources:
    DTC ClearityFoundationClinicalTrial ChemblInteractions CIViC

  • FLUOROURACIL   ERCC1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28796378 23314736 21057378 9268987


    Sources:
    NCI PharmGKB

  • FLUOROURACIL   TP53AIP1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   HLA-G

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   SLC22A16

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   PERP

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   GNL3

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   REV3L

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   DKK1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25788273


    Sources:
    CIViC

  • FLUOROURACIL   PPP2R5D

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   FOXO1

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   CCNK

    Interaction Score: 0.2

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCC5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26352872


    Sources:
    PharmGKB

  • FLUOROURACIL   HMMR

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   SELE

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24980946


    Sources:
    PharmGKB

  • FLUOROURACIL   IL6R

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8888499


    Sources:
    NCI

  • FLUOROURACIL   CDKN1A

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24708484 15067352


    Sources:
    NCI CIViC

  • FLUOROURACIL   CBR3

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   CBR1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   XRCC1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736


    Sources:
    PharmGKB

  • FLUOROURACIL   TSHB

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    603326


    Sources:
    NCI

  • FLUOROURACIL   SLC19A1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16875718


    Sources:
    PharmGKB

  • FLUOROURACIL   NOS3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29938344 25545243 19671875


    Sources:
    PharmGKB

  • FLUOROURACIL   PON1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   PTPRC

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15206578


    Sources:
    NCI

  • FLUOROURACIL   RBX1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   ALDH3A1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   SMAD4

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12237773


    Sources:
    CIViC

  • FLUOROURACIL   IRS1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   HSPA5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23456958


    Sources:
    CIViC

  • FLUOROURACIL   E2F1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9766655


    Sources:
    NCI

  • FLUOROURACIL   ITGAL

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8888499


    Sources:
    NCI

  • FLUOROURACIL   VEGFA

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25955730 24090479 20125120


    Sources:
    PharmGKB

  • FLUOROURACIL   FAS

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12845662


    Sources:
    NCI

  • FLUOROURACIL   APC

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fluorouracil + Leucovorin + Trastuzumab
    Indication/Tumor Type rectum adenocarcinoma
    Response Type no benefit

    PMIDs:
    27626067


    Sources:
    JAX-CKB

  • FLUOROURACIL   CCND1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23567490


    Sources:
    PharmGKB

  • FLUOROURACIL   CYP2E1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12904931


    Sources:
    NCI

  • FLUOROURACIL   GSTP1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27995989 21449681 18540691


    Sources:
    PharmGKB

  • FLUOROURACIL   FGFR4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16822847


    Sources:
    PharmGKB

  • FLUOROURACIL   CYP1B1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24958282


    Sources:
    PharmGKB

  • FLUOROURACIL   IL2RA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9238541


    Sources:
    NCI

  • FLUOROURACIL   ABCC4

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19696793


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCG2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24338217 24018773 20530282


    Sources:
    PharmGKB

  • FLUOROURACIL   BIRC5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15067352


    Sources:
    NCI

  • FLUOROURACIL   GNAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19274060


    Sources:
    CIViC

  • FLUOROURACIL   AURKA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25924824


    Sources:
    CIViC

  • FLUOROURACIL   BAX

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15641988


    Sources:
    NCI

  • FLUOROURACIL   CYP2C8

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   SLCO1B1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27234217


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCC2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23314736


    Sources:
    PharmGKB

  • FLUOROURACIL   HBB

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FLUOROURACIL   BDNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18702703


    Sources:
    NCI

  • FLUOROURACIL   BRAF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fluorouracil + Leucovorin + Trastuzumab
    Indication/Tumor Type rectum adenocarcinoma
    Response Type no benefit

    PMIDs:
    26637369 27626067


    Sources:
    JAX-CKB

  • FLUOROURACIL   KRAS

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Panitumumab + Oxaliplatin + Fluorouracil + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type no benefit

    PMIDs:
    26341920 20921465


    Sources:
    JAX-CKB CIViC

  • FLUOROURACIL   CYP19A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   PIK3CA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Fluorouracil + Cetuximab
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871 28424201 22336586


    Sources:
    JAX-CKB

  • FLUOROURACIL   PIK3R2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   ERBB2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma

    PMIDs:
    27626067 28784859 26432108


    Sources:
    JAX-CKB

  • FLUOROURACIL   NOS1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   MET

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Trastuzumab + Fluorouracil + Leucovorin + Oxaliplatin
    Indication/Tumor Type gastric adenocarcinoma
    Response Type resistant

    PMIDs:
    26432108


    Sources:
    JAX-CKB

  • FLUOROURACIL   ATM

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   INSR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   TOP2A

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   EGFR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23816762


    Sources:
    PharmGKB

  • FLUOROURACIL   PTEN

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • FLUOROURACIL   ABCB1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16892554


    Sources:
    NCI

  • FLUOROURACIL   TP53

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC PharmGKB

  • FLUOROURACIL   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12904931


    Sources:
    NCI

  • FLUOROURACIL   CYP2C19

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NCI: FLUOROURACIL

    • Version: 14-September-2017

    Alternate Names:
    C505 NCI drug code

    Drug Info:

    Publications:
    Hisamitsu et al., Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma., Anticancer Res.
    Hirano et al., Thymidine phosphorylase activity in transitional cell cancer: relation to histological parameters and chemosensitivity to fluorouracil-related drugs., Anticancer Res.

  • NCI: 5-FU

    • Version: 14-September-2017

    Alternate Names:
    C505 NCI drug code

    Drug Info:

    Publications:
    Tajima et al., 2003, Association of gastric and intestinal phenotypic marker expression of gastric carcinomas with tumor thymidylate synthase expression and response to postoperative chemotherapy with 5-fluorouracil., J. Cancer Res. Clin. Oncol.
    de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.
    Mustafa et al., 2008, 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus., Eur. J. Neurosci.

  • NCI: 5-FLUOROURACIL

    • Version: 14-September-2017

    Alternate Names:
    C505 NCI drug code

    Drug Info:

    Publications:
    Musashi et al., 1991, Synergistic interactions between interleukin-11 and interleukin-4 in support of proliferation of primitive hematopoietic progenitors of mice., Blood
    Ciaparrone et al., 2006, Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil., Oncology
    Araki et al., 2001, Dihydropyrimidine dehydrogenase activity and thymidylate synthase level are associated with response to 5-fluorouracil in human colorectal cancer., Kurume Med J

  • DTC: FLUOROURACIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL185 ChEMBL Drug ID

    Drug Info:

    Publications:
    Pelà M et al., 2014, Optimization of peptides that target human thymidylate synthase to inhibit ovarian cancer cell growth., J Med Chem

  • JAX-CKB: 5-FU

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Bhattacharya et al., 2012, Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells., Cancer Biol. Ther.

  • JAX-CKB: Fluorouracil

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Peeters et al., 2015, Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer., Clin. Cancer Res.
    Aung et al., 2016, Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer., Cold Spring Harb Mol Case Stud

  • PharmGKB: fluorouracil

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
    Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
    Kalra S et al., 2018, Association of CYP2C19*2 and ALDH1A1*1/*2 variants with disease outcome in breast cancer patients: results of a global screening array., Eur J Clin Pharmacol

  • CIViC: FLUOROURACIL

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tamotsu et al., 2015, Correlation of Aurora-A expression with the effect of chemoradiation therapy on esophageal squamous cell carcinoma., BMC Cancer
    Huang et al., 2009, The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population., Cancer Chemother. Pharmacol.
    Nikas et al., 2015, A common variant in MTHFR influences response to chemoradiotherapy and recurrence of rectal cancer., Am J Cancer Res

  • TTD: Fluorouracil

    • Version: 2020.06.01

    Alternate Names:
    D05LEO TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL185

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Fluorouracil

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL185

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: FLUOROURACIL

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: 5-FLUOROURACIL

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21